Faropenem, a stable and orally bioavailable β-lactam, to
counteract resistant pathogens and infectious diseases. A narrative
review
Authors: Dr Amit Bhalla; Affiliations: Uniza Healthcare LLP; email:
amitbhll@yahoo.com
Abstract:
Antimicrobial resistance is a huge challenge for the effective
prevention and treatment of infectious diseases worldwide.
Community-onset infections with Extended-spectrum β-lactamases (ESBL)
producing bacteria are a challenge. In various studies, ESBL-producing
isolates were consistently susceptible only to carbapenems. When
treatment with other antibiotics fails, carbapenems are used as the
last-line antibiotics for treating severe and/or resistant bacterial
infections. In this narrative review, we aim to present the pharmacology
of Faropenem, which is an orally administered penem antibiotic with a
broad-spectrum activity against many Gram-positive and Gram-negative
aerobes, and anaerobes.
Faropenem is effective in the treatment of uncomplicated cystitis and is
a potential solution to combat the emergence of resistance among
respiratory tract pathogens. It is an alternative to fluoroquinolones or
macrolides/ketolides when there is a concern with resistant pathogens.
Keywords: β-lactamases, Carbapenems, Faropenem.